Dr Jakob Kirkegård

Leveraging the power of data to improve pancreatic cancer treatment

Jakob Kirkegård is a physician, associate professor, and now also a doctor at Aarhus University's Department of Clinical Medicine and Aarhus University Hospital. He has just obtained his doctoral degree in the surgical treatment of pancreatic cancer – one of the most deadly forms of cancer.

Portrait photo of Jakob Kirkegard
Jakob Kirkegård is a newly appointed doctor in the surgical treatment of pancreatic cancer and is affiliated with both the Department of Clinical Medicine and the Department of Surgery at Aarhus University Hospital.

Image source: Aarhus University; photo: private

Pancreatic cancer is known for its aggressive nature and poor prognosis. Jakob Kirkegård therefore hopes that through his research, he can pave the way for more targeted and effective treatment methods for patients with the disease. 

“My research is significant in being able to target and improve the treatment of future patients with pancreatic cancer. By analyzing large amounts of patient data and conducting clinical trials, my research colleagues and I hope to increase survival rates and improve the quality of life for the patients,” says Jakob Kirkegård, and continues: “It is specifically about getting better at diagnosing the disease earlier so that more patients can undergo surgery, but also about optimizing the surgical treatment.” 

Jakob Kirkegård defended his doctoral dissertation on May 2nd, which integrates epidemiology, diagnostics, surgical treatment, and prognosis – all focused on the fight against pancreatic cancer.

Source: Aarhus University

16.05.2025

Related articles

Photo

News • Prognostic role of IPMNs

Nodules key to avoid unneccessary pancreatic cancer surgery

Pancreatic cysts (IPMNs) are seen as a precursor of pancreatic cancer. However, not all patients need to undergo surgery. A recent study may help patients with IPMNs to avoid unnecessary surgery.

Photo

News • Trial finds improved survival rates

Pancreatic cancer: chemotherapy before surgery brings benefits

Treating pancreatic cancer patients with chemotherapy before surgery significantly improved 1-year survival rates compared to immediate surgery, a randomised clinical trial has found.

Photo

News • Interferon response cancer-associated fibroblasts

Pancreatic cancer: Cell discovery opens up new research avenues

A newly discovered type of cells counteract tumor development and may therefore be a target for research into new treatments for pancreatic cancer, which is one of the deadliest forms of cancer.

Related products

Subscribe to Newsletter